| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ERBB3; HER3; Receptor tyrosine-protein kinase erbB-3; Proto-oncogene-like protein c-ErbB-3; Tyrosine kinase-type cell surface receptor HER3 |
| Entrez GeneID | 2065 |
| WB Predicted band size | Calculated MW: 148 kDa; Observed MW: 185 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human ErbB 3 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3篇关于ErbB3(HER3)抗体的研究文献摘要示例：
---
1. **文献名称**：*Therapeutic targeting of HER3: A key node in ligand-induced activation of ErbB signaling networks*
**作者**：Schoeberl, B. et al.
**摘要**：研究揭示了HER3在EGFR信号网络中的核心作用，开发了一种新型抗HER3抗体，通过阻断配体(如heregulin)依赖性激活，抑制下游PI3K/AKT通路，在多种实体瘤模型中显示抗肿瘤活性。
---
2. **文献名称**：*Patritumab, a first-in-class anti-HER3 antibody, enhances EGFR inhibitor efficacy in KRAS-mutant colorectal cancer models*
**作者**：Yonesaka, K. et al.
**摘要**：报道了抗HER3抗体Patritumab与西妥昔单抗(EGFR抑制剂)联用，可克服KRAS突变型结直肠癌的耐药性，机制涉及抑制HER3-EGFR异源二聚体形成及下游信号通路激活。
---
3. **文献名称**：*HER3-specific antibody-drug conjugates for targeted therapy of HER3-dependent cancers*
**作者**：Li, C. et al.
**摘要**：开发了一种HER3靶向的抗体-药物偶联物(ADC)，通过特异性结合HER3并递送细胞毒性载荷，在乳腺癌和肺癌异种移植模型中显著抑制肿瘤生长，且安全性可控。
---
如需具体文献信息，可进一步提供PubMed ID或DOI以精准定位原文。
The ErbB3 receptor (also known as HER3) is a member of the epidermal growth factor receptor (EGFR) tyrosine kinase family, which includes EGFR (HER1), HER2. and HER4. Unlike other family members, ErbB3 lacks intrinsic kinase activity and relies on heterodimerization with other ErbB receptors, particularly HER2. to activate downstream signaling pathways such as PI3K/AKT and MAPK. These pathways regulate cell proliferation, survival, and differentiation. ErbB3 is activated by neuregulins (NRGs) and is frequently overexpressed or aberrantly activated in cancers, including breast, lung, and colorectal tumors, contributing to tumor progression, metastasis, and resistance to targeted therapies (e.g., HER2- or EGFR-directed agents).
ErbB3-targeting antibodies are designed to block ligand binding, inhibit receptor dimerization, or induce receptor internalization/degradation, thereby suppressing oncogenic signaling. Examples include lumretuzumab, patritumab, and seribantumab, which have undergone clinical trials, often in combination with other therapies. Challenges include identifying predictive biomarkers, overcoming compensatory signaling, and managing toxicity. Recent research also explores bispecific antibodies or antibody-drug conjugates to enhance efficacy. Despite limited success as monotherapy, ErbB3 antibodies hold promise in combinatorial strategies, particularly in tumors with NRG-dependent resistance mechanisms. Ongoing studies aim to refine patient selection and optimize therapeutic protocols based on ErbB3’s complex role in tumor microenvironment interactions and adaptive signaling.
×
